PULMONARY REHABILITATION AND QUALITY OF LIFE IN LUNG CANCER PATIENTS
Abstract
Lung cancer is one of the most common types of cancer, often diagnosed in advanced stages. Chest surgery is the main component of curative treatment, the pre-operative functional status being predictive for post-operative morbidity. The potential benefits of pulmonary rehabilitation in lung cancer management appear in pre-operative period, improving the exercise capacity and increasing the number of patients sent to surgery, in post-operative period, decreasing the number of complications, and during the medical treatment of patients with advanced disease, improving the symptoms and increasing the quality of life. The quality of life (QOL) in patients with lung cancer is determined by factors related to patient (stage of disease, co morbidities) as well as treatment (surgery, chemotherapy, radiotherapy). The assessment of QOL is made through questionnaires, mainly related to therapeutic regimens and symptoms. Among the most used are Questionnaire of the European Organization for Research and Treatment of Cancer (EORTC QLQ - C30), Functional Assessment of Cancer Therapy - General (FACT - G), FACT - L (Lung) and the Lung Cancer Symptom Scale (LCSS).
References
2. Camps C, del Pozo N, Blasco A, Blasco P, Sirera R. Importance of quality of life in patients with non-small-cell lung cancer. Clin Lung Cancer 2009; 10: 83–90.
3. Glattki GP, Manika K, Sichletidis L, Alexe G, Brenke R, Spyratos D. Pulmonary rehabilitation in non-small cell lung cancer patients after completion of treatment. Am J Clin Oncol 2012; 35(2): 120-125.
4. Ries AL, Bauldoff GS, Carlin BW et al. Pulmonary rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S-42S DOI: 10.1378/chest.06-2418.
5. Nici L, ZuWallack R. Pulmonary rehabilitation: today and tomorrow. Breathe 2010; 6(4): 305-311.
6. Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C et al. An official American Tho-racic Society/European Respiratory Society statement: key concepts and advances in pulmonary re-habilitation. Am J Respir Crit Care Med 2013; 188(8): e13-e64 DOI: 10.1164/rccm.201309-1634ST.
7. Bobbio A, Chetta A, Ampollini L, Primomo GL, Internullo E, Carbognani P et al. Preoperative pul-monary rehabilitation in patients undergoing lung resection for non–small cell lung cancer. Eur J Cardiothorac Surg 2008; 33: 95–98.
8. Jones LW, Peddle CJ, Eves ND, Haykowsky MJ, Courneya KS, Mackey JR et al. Effects of presurgi-cal exercise training on cardiorespiratory fitness among patients undergoing thoracic surgery for ma-lignant lung lesions. Cancer 2007; 110: 590–598.
9. Benzo R, Wigle D, Novotny P, Wetzstein M, Nichols F, Shen RK et al. Preoperative pulmonary rehabilitation before lung cancer resection: results from two randomized studies. Lung Cancer 2011; 74: 441-445.
10. Cesario A, Ferri L, Galetta D, Pasqua F, Bonassi S, Clini E et al. Post-operative respiratory rehabili-tation after lung resection for non-small cell lung cancer. Lung Cancer 2007; 57: 175-180.
11. Bradley A, Marshall A, Stonehewer L, Reaper L, Parker K, Bevan-Smith E et al. Pulmonary rehabili-tation programme for patients undergoing curative lung cancer surgery. Eur J Cardiothorac Surg 2013; 44(4): e266-e271 doi: 10.1093/ejcts/ezt381.
12. Spruit MA, Janssen PP, Willemsen SC, Hochstenbag MM, Wouters EF. Exercise capacity before and after an 8-week multidisciplinary inpatient rehabilitation program in lung cancer patients: a pilot study. Lung Cancer 2006; 52: 257–260.
13. Jones LW, Eves ND, Peterson BL, Garst J, Crawford J, West MJ et al. Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical non-small cell lung cancer patients: a pilot study. Cancer 2008; 113: 3430–3439.
14. Granger CL, McDonald CF, Berney S, Chao C, Denehy L. Exercise intervention to improve exercise capacity and health related quality of life for patients with non–small cell lung cancer: a systematic review. Lung Cancer 2011; 72: 139–153.
15. Jones LW, Eves ND, Kraus WE, Potti A, Crawford J, Blumenthal JA, Peterson BL, Douglas PS. The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. BMC Cancer 2010; 10: 155-159.
16. Ozalevli S, Ilgin D, Kul Karaali H, Bulac S, Akkoclu A. The effect of in-patient chest physiotherapy in lung cancer patients. Support Care Cancer 2010; 18: 351–358.
17. Payne C, Larkin PJ, Mcllfatrick S, Dunwoody L, Gracey JH. Exercise and nutrition interventions in advanced lung cancer: a systematic review. Curr Oncol 2013; 20(4): e321-e337.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al. The European organiza-tion for research and treatment of cancer QLQ-C30: a quality-of life instrument for use in international clinical trials in oncology. J Natl. Cancer Inst 1993; 85: 365–376.
19. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, Silberman M,Yellen SB, Winicour P, Brannon J. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570–579.
20. Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev 2013; 3: 15.
21. Booton R, Lorigan P, Anderson H, Baka S, Ashcroft L, Nicolson M et al. A phase III trialof docet-axel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) ormitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small cell lung cancer: a randomized multicenter trial of the British thoracic oncology group (BTOG1). Ann Oncol 2006; 17: 1111–1119.
22. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN investigators and the national cancer institute of Canada clinical trials group. J Clin Oncol 2003; 21: 3025–3034.
23. Schumacher A, Riesenbeck D, Braunheim M, Wewers D, Heinecke A, SemikM et al. German Lung Cancer Cooperative Group: Combined modality treatment for locally advanced non-small cell lung cancer: preoperative chemoradiation does not result in a poorer quality of life. Lung Cancer 2004; 44: 89–97.
24. Grønberg BH, Bremnes RM, Fløtten O, Amundsen T, Brunsvig PF, Hjelde HH et al. Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non–small cell lung cancer. J Clin Oncol 2009; 27: 3217–3224.
25. Paccagnella A, Favaretto A, Oniga F, Barbieri F, Ceresoli G, Torri W et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non-small cell lung cancer. A multicenter, randomized phase III trial. Lung Cancer 2004; 43: 83–91.
26. Belani CP, Pereira JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E et al. Effect of chemo-therapy for advanced non-small cell lung cancer on patients’ quality of life – a randomized controlled trial. Lung Cancer 2006; 53: 231–239.
27. Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R et al. Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years’ follow-up results from a randomised phase III trial. Lung Cancer 2006; 53: 67–75.
28. Gelibter A, Ceribelli A, Pollera CF, Milella M, Moscetti L, Sperduti I, Cognetti F. Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer. J Cancer Res Clin Oncol 2005; 131: 783–788.
29. Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH et al. Clinically meaningful im-provement in symptoms and quality of life for patients with non–small cell lung cancer receiving ge-fitinib in a randomized controlled trial. J Clin Oncol 2005; 23: 2946–2954.
30. Lilenbaum R, Axelrod R, Thomas S, Dowlati A, Seigel L, Albert D et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small cell lung cancer and a per-formance status of 2. J Clin Oncol 2008; 26: 863–869.
31. Bezjak A, Tu D, Seymour L, Clark G, Trajkovic A, Zukin M et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the national cancer institute of Canada clinical trials group study BR.21. J Clin Oncol 2006; 24: 3831–3837.
32. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS et al. Symptom Control and Quali-ty of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR Mutations. J Clin Oncol 2013; 31(27): 3342-3350.
33. Sirzén F, Kjellén E, Sörenson S, Cavallin–Ståhl E. A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol 2003; 42: 493–515.
34. Langendijk JA, Aaronson NK, ten Velde GP, de Jong JM, Muller MJ, Wouters EF. Pretreatment quality of life of inoper¬able non-small cell lung cancer patients referred for primary radiotherapy. Acta Oncol 2000; 39: 949–958.
35. Medical Research Council Lung Cancer Working Party. Randomized trial of palliative two-fraction versus more intensive thirteen fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Clin Oncol 1996; 8: 167-175.
36. Reinfuss M, Glinski B, Kowalska T et al. Radiotherapy in stage III, unresectable, asymptomatic non-small cell lung cancer. Final results of a prospective randomized study of 240 patients. Cancer Radi-other 1999; 3: 475-479.
37. Ung YC, Yu E, Falkson C et al. The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small cell lung cancer: a systematic review. Brachytherapy 2006; 5: 189-202.
38. Hirsh V, Soulieres D, Duclos M et al. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gem-citabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol 2007; 2: 927-932.
39. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic ob-structive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000; 55: 1000-1006.

Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form